logo-loader
viewAmryt Pharma PLC

Amryt Pharma completes on 'transformational' acquisition and US$60mln fundraise

Amryt Pharma PLC's (LON:AMYT) Joe Wiley speaks to Proactive London's Andrew Scott as the firm completed on what he describes as a transformational acquisition and, backed by shareholders, a US$60mln fundraise.

The transaction, which gives Amryt full control of the Lojuxta cholesterol treatment, creates an international business that would have generated revenues of US$136.5mln last year.

Quick facts: Amryt Pharma PLC

Price: 117.5 GBX

AIM:AMYT
Market: AIM
Market Cap: £181.54 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Amryt Pharma well positioned to become 'global leader in...

Amryt Pharma PLC's (LON:AMYT) Rory Nealon talks Proactive London's Andrew Scott through their trading update for the nine months to the end of September 2019. It's a period in which Amryt completed the acquisition of Aegerion Pharmaceuticals Inc and saw the firm go from a single-product,...

on 5/11/19

2 min read